Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype

Masayuki Nitta, Yoshihiro Muragaki, Takashi Maruyama, Hiroshi Iseki, Soko Ikuta, Yoshiyuki Konishi, Taichi Saito, Manabu Tamura, Michael Chernov, Atsushi Watanabe, Saori Okamoto, Katsuya Maebayashi, Norio Mitsuhashi, Yoshikazu Okada

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The importance of surgical resection for patients with supratentorial low-grade glioma (LGG) remains controversial. This retrospective study of patients (n = 153) treated between 2000 to 2010 at a single institution assessed whether increasing the extent of resection (EOR) was associated with improved progression-free survival (PFS) and overall survival (OS). Histological subtypes of World Health Organization grade II tumors were as follows: diffuse astrocytoma in 49 patients (32.0%), oligoastrocytoma in 45 patients (29.4%), and oligodendroglioma in 59 patients (38.6%). Median pre-and postoperative tumor volumes and median EOR were 29.0 cm3 (range 0.7-162 cm3) and 1.7 cm3 (range 0-135.7 cm3) and 95%, respectively. Five- and 10-year OS for all LGG patients were 95.1% and 85.4%, respectively. Eight-year OS for diffuse astrocytoma, oligoastrocytoma, and oligodendroglioma were 70.7%, 91.2%, and 98.3%, respectively. Five-year PFS for diffuse astrocytoma, oligoastrocytoma, and oligodendroglioma were 42.6%, 71.3%, and 62.7%, respectively. Patients were divided into two groups by EOR ≥90% and <90%, and OS and PFS were analyzed. Both OS and PFS were significantly longer in patients with ≥90% EOR. Increased EOR resulted in better PFS for diffuse astrocytoma but not for oligodendroglioma. Multivariate analysis identified age and EOR as parameters significantly associated with OS. The only parameter associated with PFS was EOR. Based on these findings, we established updated therapeutic strategies for LGG. If surgery resulted in EOR <90%, patients with astrocytoma will require second-look surgery, whereas patients with oligodendroglioma or oligoastrocytoma, which are sensitive to chemotherapy, will be treated with chemotherapy.

Original languageEnglish
Pages (from-to)447-454
Number of pages8
JournalNeurologia Medico-Chirurgica
Volume53
Issue number7
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Glioma
Oligodendroglioma
Astrocytoma
Disease-Free Survival
Neoplasms
Survival
Therapeutics
Second-Look Surgery
Drug Therapy
Tumor Burden
Multivariate Analysis
Retrospective Studies

Keywords

  • Extent of resection
  • Low-grade glioma
  • Residual tumor volume
  • Survival
  • Treatment strategy

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Nitta, M., Muragaki, Y., Maruyama, T., Iseki, H., Ikuta, S., Konishi, Y., ... Okada, Y. (2013). Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype. Neurologia Medico-Chirurgica, 53(7), 447-454. https://doi.org/10.2176/nmc.53.447

Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype. / Nitta, Masayuki; Muragaki, Yoshihiro; Maruyama, Takashi; Iseki, Hiroshi; Ikuta, Soko; Konishi, Yoshiyuki; Saito, Taichi; Tamura, Manabu; Chernov, Michael; Watanabe, Atsushi; Okamoto, Saori; Maebayashi, Katsuya; Mitsuhashi, Norio; Okada, Yoshikazu.

In: Neurologia Medico-Chirurgica, Vol. 53, No. 7, 2013, p. 447-454.

Research output: Contribution to journalArticle

Nitta, M, Muragaki, Y, Maruyama, T, Iseki, H, Ikuta, S, Konishi, Y, Saito, T, Tamura, M, Chernov, M, Watanabe, A, Okamoto, S, Maebayashi, K, Mitsuhashi, N & Okada, Y 2013, 'Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype', Neurologia Medico-Chirurgica, vol. 53, no. 7, pp. 447-454. https://doi.org/10.2176/nmc.53.447
Nitta, Masayuki ; Muragaki, Yoshihiro ; Maruyama, Takashi ; Iseki, Hiroshi ; Ikuta, Soko ; Konishi, Yoshiyuki ; Saito, Taichi ; Tamura, Manabu ; Chernov, Michael ; Watanabe, Atsushi ; Okamoto, Saori ; Maebayashi, Katsuya ; Mitsuhashi, Norio ; Okada, Yoshikazu. / Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype. In: Neurologia Medico-Chirurgica. 2013 ; Vol. 53, No. 7. pp. 447-454.
@article{6dea1a71af7d4238acca9dc6c3bd0cff,
title = "Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype",
abstract = "The importance of surgical resection for patients with supratentorial low-grade glioma (LGG) remains controversial. This retrospective study of patients (n = 153) treated between 2000 to 2010 at a single institution assessed whether increasing the extent of resection (EOR) was associated with improved progression-free survival (PFS) and overall survival (OS). Histological subtypes of World Health Organization grade II tumors were as follows: diffuse astrocytoma in 49 patients (32.0{\%}), oligoastrocytoma in 45 patients (29.4{\%}), and oligodendroglioma in 59 patients (38.6{\%}). Median pre-and postoperative tumor volumes and median EOR were 29.0 cm3 (range 0.7-162 cm3) and 1.7 cm3 (range 0-135.7 cm3) and 95{\%}, respectively. Five- and 10-year OS for all LGG patients were 95.1{\%} and 85.4{\%}, respectively. Eight-year OS for diffuse astrocytoma, oligoastrocytoma, and oligodendroglioma were 70.7{\%}, 91.2{\%}, and 98.3{\%}, respectively. Five-year PFS for diffuse astrocytoma, oligoastrocytoma, and oligodendroglioma were 42.6{\%}, 71.3{\%}, and 62.7{\%}, respectively. Patients were divided into two groups by EOR ≥90{\%} and <90{\%}, and OS and PFS were analyzed. Both OS and PFS were significantly longer in patients with ≥90{\%} EOR. Increased EOR resulted in better PFS for diffuse astrocytoma but not for oligodendroglioma. Multivariate analysis identified age and EOR as parameters significantly associated with OS. The only parameter associated with PFS was EOR. Based on these findings, we established updated therapeutic strategies for LGG. If surgery resulted in EOR <90{\%}, patients with astrocytoma will require second-look surgery, whereas patients with oligodendroglioma or oligoastrocytoma, which are sensitive to chemotherapy, will be treated with chemotherapy.",
keywords = "Extent of resection, Low-grade glioma, Residual tumor volume, Survival, Treatment strategy",
author = "Masayuki Nitta and Yoshihiro Muragaki and Takashi Maruyama and Hiroshi Iseki and Soko Ikuta and Yoshiyuki Konishi and Taichi Saito and Manabu Tamura and Michael Chernov and Atsushi Watanabe and Saori Okamoto and Katsuya Maebayashi and Norio Mitsuhashi and Yoshikazu Okada",
year = "2013",
doi = "10.2176/nmc.53.447",
language = "English",
volume = "53",
pages = "447--454",
journal = "Neurologia Medico-Chirurgica",
issn = "0387-2572",
publisher = "Japan Neurosurgical Society",
number = "7",

}

TY - JOUR

T1 - Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype

AU - Nitta, Masayuki

AU - Muragaki, Yoshihiro

AU - Maruyama, Takashi

AU - Iseki, Hiroshi

AU - Ikuta, Soko

AU - Konishi, Yoshiyuki

AU - Saito, Taichi

AU - Tamura, Manabu

AU - Chernov, Michael

AU - Watanabe, Atsushi

AU - Okamoto, Saori

AU - Maebayashi, Katsuya

AU - Mitsuhashi, Norio

AU - Okada, Yoshikazu

PY - 2013

Y1 - 2013

N2 - The importance of surgical resection for patients with supratentorial low-grade glioma (LGG) remains controversial. This retrospective study of patients (n = 153) treated between 2000 to 2010 at a single institution assessed whether increasing the extent of resection (EOR) was associated with improved progression-free survival (PFS) and overall survival (OS). Histological subtypes of World Health Organization grade II tumors were as follows: diffuse astrocytoma in 49 patients (32.0%), oligoastrocytoma in 45 patients (29.4%), and oligodendroglioma in 59 patients (38.6%). Median pre-and postoperative tumor volumes and median EOR were 29.0 cm3 (range 0.7-162 cm3) and 1.7 cm3 (range 0-135.7 cm3) and 95%, respectively. Five- and 10-year OS for all LGG patients were 95.1% and 85.4%, respectively. Eight-year OS for diffuse astrocytoma, oligoastrocytoma, and oligodendroglioma were 70.7%, 91.2%, and 98.3%, respectively. Five-year PFS for diffuse astrocytoma, oligoastrocytoma, and oligodendroglioma were 42.6%, 71.3%, and 62.7%, respectively. Patients were divided into two groups by EOR ≥90% and <90%, and OS and PFS were analyzed. Both OS and PFS were significantly longer in patients with ≥90% EOR. Increased EOR resulted in better PFS for diffuse astrocytoma but not for oligodendroglioma. Multivariate analysis identified age and EOR as parameters significantly associated with OS. The only parameter associated with PFS was EOR. Based on these findings, we established updated therapeutic strategies for LGG. If surgery resulted in EOR <90%, patients with astrocytoma will require second-look surgery, whereas patients with oligodendroglioma or oligoastrocytoma, which are sensitive to chemotherapy, will be treated with chemotherapy.

AB - The importance of surgical resection for patients with supratentorial low-grade glioma (LGG) remains controversial. This retrospective study of patients (n = 153) treated between 2000 to 2010 at a single institution assessed whether increasing the extent of resection (EOR) was associated with improved progression-free survival (PFS) and overall survival (OS). Histological subtypes of World Health Organization grade II tumors were as follows: diffuse astrocytoma in 49 patients (32.0%), oligoastrocytoma in 45 patients (29.4%), and oligodendroglioma in 59 patients (38.6%). Median pre-and postoperative tumor volumes and median EOR were 29.0 cm3 (range 0.7-162 cm3) and 1.7 cm3 (range 0-135.7 cm3) and 95%, respectively. Five- and 10-year OS for all LGG patients were 95.1% and 85.4%, respectively. Eight-year OS for diffuse astrocytoma, oligoastrocytoma, and oligodendroglioma were 70.7%, 91.2%, and 98.3%, respectively. Five-year PFS for diffuse astrocytoma, oligoastrocytoma, and oligodendroglioma were 42.6%, 71.3%, and 62.7%, respectively. Patients were divided into two groups by EOR ≥90% and <90%, and OS and PFS were analyzed. Both OS and PFS were significantly longer in patients with ≥90% EOR. Increased EOR resulted in better PFS for diffuse astrocytoma but not for oligodendroglioma. Multivariate analysis identified age and EOR as parameters significantly associated with OS. The only parameter associated with PFS was EOR. Based on these findings, we established updated therapeutic strategies for LGG. If surgery resulted in EOR <90%, patients with astrocytoma will require second-look surgery, whereas patients with oligodendroglioma or oligoastrocytoma, which are sensitive to chemotherapy, will be treated with chemotherapy.

KW - Extent of resection

KW - Low-grade glioma

KW - Residual tumor volume

KW - Survival

KW - Treatment strategy

UR - http://www.scopus.com/inward/record.url?scp=84880842139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880842139&partnerID=8YFLogxK

U2 - 10.2176/nmc.53.447

DO - 10.2176/nmc.53.447

M3 - Article

C2 - 23883555

AN - SCOPUS:84880842139

VL - 53

SP - 447

EP - 454

JO - Neurologia Medico-Chirurgica

JF - Neurologia Medico-Chirurgica

SN - 0387-2572

IS - 7

ER -